Powered by Smartsupp

Type 2 diabetes and laser blood irradiation: encouraging research findings

KINGRAY Academy logo
KINGRAY ACADEMY
LASER SERIES · 09 · TYPE 2 DIABETES

Could light affect blood glucose, diabetic wound healing or neuropathic pain? We examine human studies, explain their findings and distinguish between the different ways light is applied.

Author: Ing. František Kokoš
Updated:

How is blood irradiation performed, and what is photobiomodulation?

Photobiomodulation (PBM) is the broader term for influencing biological processes using light with defined parameters. Laser blood irradiation is just one area of this research. Diabetes studies have also investigated LED sources over muscles and local treatment of the foot.

  • Intravenous ILIB: light is delivered into a vein through an optical fibre. This is an invasive procedure performed in a healthcare setting. [1][2]
  • Transcutaneous vascular PBM: an applicator is placed on the skin over a blood vessel, for example at the wrist. The skin is not punctured. [3][6]
  • Intranasal PBM: light is applied to the nasal mucosa. This is a different delivery route; the diabetes studies discussed below did not directly test it.
  • Local PBM: light is directed at a specific tissue, such as a muscle, the area around a wound or the foot. [4][7][8]

Terminology also matters: some authors use “ILIB” for application through the skin. In the 2026 neuropathy pilot study, the applicator was on the wrist even though the title refers to ILIB. [9]

How might light influence cellular energy and glucose?

One research hypothesis links PBM to mitochondrial activity and production of ATP, the molecule cells use to transfer energy. Changes in energy metabolism could also influence glucose utilisation. This mechanism is being investigated, for example, with light applied over muscle areas. It does not mean light directly “dissolves” glucose or that everybody will respond in the same way. [4][5]

Can lasers lower blood glucose? What have human studies found?

Yes, published studies have reported favourable changes in blood glucose. However, they vary in size, application method and outcomes. We therefore examine them individually:

2013 · An early metabolomic signal

9 patients with type 2 diabetes. Following intravenous blue light, the authors observed lower glucose and changes in several metabolites. This provides a reason to investigate the mechanisms. However, the very small sample and a before-and-after comparison without a control group cannot separate the light effect from other influences. [1]

2015 · Blue and red light during ILIB

24 patients with type 2 diabetes. The authors compared intravenous application at 405 and 632.8 nm. They observed lower glucose with both, but no significant difference between the colours. This small comparative study does not establish a universally superior colour or a home-use protocol. [2]

2021 · A randomised study with 60 patients

Two groups of 30 people, 12 weeks. One received prescribed medication plus 650 nm light through the skin; the other received medication alone. Mean HbA1c changed from 7.65 to 6.47%, compared with 7.60 to 6.97% in the comparison group. The post-intervention difference in fasting glucose was also favourable. The result supports further trials, but the control group received no sham light treatment and independent replication is needed. [3]

2023 · LED light over muscle areas

10 patients in a randomised crossover trial with an inactive control. The study tested 830 nm LEDs over several muscle areas. Glucose responded to dose and timing; differences between regimens were less clear with concurrent medication. Observation lasted hours. This was not a nasal laser study or evidence of long-term HbA1c improvement. [4]

2024 · Red light and a glucose test in healthy people

30 healthy participants, not patients with diabetes. After 670 nm light, the authors reported a smaller overall glucose rise during a two-hour test and a lower peak. The frequently cited 27.7% describes a reduction in the integrated rise after a glucose challenge, not a 27.7% reduction in everybody’s usual glucose level. This interesting experiment also needs testing in diabetes. [5]

2026 · Vascular PBM through the skin at the wrist

15 patients taking metformin, six weeks. With 660 nm application, the authors observed a fall in mean fasting glucose from approximately 8.97 to 7.24 mmol/L. HbA1c did not change significantly. Without a control group, it is impossible to establish how much of the change was caused by light; usual treatment and exercise also continued. [6]

Why one reading is not enough: glucose, HbA1c and remission

Blood glucose shows the current glucose concentration. It changes after meals, exercise and throughout the day. HbA1c reflects average glucose over roughly three months and helps assess longer-term control. [13]

In the 12-week controlled study, HbA1c improved more in the light group. In the six-week uncontrolled study, it did not change significantly. These are different results; we cannot select only the more favourable one. Neither alone establishes lasting diabetes remission. [3][6]

Is red or blue light better?

The small comparative ILIB study found no significant difference in the observed glucose reduction between blue light at 405 nm and red light at 632.8 nm. This does not mean all colours and devices are interchangeable. [2]

Application site, power over the treated area, duration and repetition also matter. A result from intravenous blue light is not an instruction to shine blue light into the nose. The article on wavelength, power and time explains these parameters.

A definitive treatment or a promising research direction?

For diabetes control, PBM is a promising adjunctive approach under investigation. These studies provide reasons for further research, not evidence that light can replace medication, diet, exercise or diabetes check-ups. Application methods and concurrent treatments vary across studies. [3][4][6]

What should future research establish? Whether the effect is replicated in larger groups with an inactive control device, persists for months, changes HbA1c or hypoglycaemia rates, and benefits specific complications. Nasal application needs its own clinical diabetes data, rather than results transferred from wrist treatment.

Home devices and cost: what should you ask?

Home light devices do exist, and a particular local home laser has been studied for neuropathic foot pain. However, that device, its intended purpose and protocol cannot be equated with any watch, panel or nasal applicator. [8]

Before choosing a device, check its intended purpose, suitable application site, instructions, eye protection, restrictions relevant to your health and clinical evidence for the specific goal. A “wellness” label alone is not evidence of diabetes treatment. Do not use this article to set your own dose or shorten prescribed treatment.

How much does a procedure or device cost?

There is no single price. For a clinical procedure, compare the cost of the complete course, including examination and follow-up. For a home device, consider the model, necessary applicators and servicing. A generic price without a specific service and country would be misleading. Our light advice section helps explain device types; current prices belong to individual offers.

Is photobiomodulation safe in diabetes?

Safety must be assessed for the particular device, dose, application site and health condition. “Low-level” does not mean risk-free: in the 2026 vascular PBM study, two participants reported temporary local burning and redness. [6]

Diabetic neuropathy can reduce sensitivity to pain and heat. A person may therefore fail to notice skin damage promptly. Injury, infection, markedly impaired circulation or reduced sensation require individual assessment; a diabetic foot wound is not suitable for home experimentation. [12]

Follow the contraindications and eye-protection instructions supplied with the device. Exclusion criteria from one study are not a universal contraindication list for all light devices. If burning or another new problem occurs during use, stop the application and discuss the cause with a healthcare professional.

Could hypoglycaemia occur?

We cannot yet reliably quantify the exact risk for individual PBM protocols. If glucose reduction is being investigated, monitoring excessively low values must be part of safety assessment. Particular attention is needed for people taking insulin or sulfonylureas, which can cause hypoglycaemia. Do not adjust your medication yourself because of light treatment. [4][11]

Before adding an adjunctive approach, agree a glucose-monitoring plan and a response to low readings with your diabetes clinician. If conscious and able to swallow safely, a value below 3.9 mmol/L is usually managed with 15–20 g of rapidly absorbed glucose and a recheck after 15 minutes, following the individual plan. If unconscious or unable to swallow, give nothing by mouth and call emergency services. [11]

Diabetic foot wounds and neuropathy: where else are there positive findings?

Wound healing: local application at 904 nm

A 2024 randomised study included 80 people with non-infected diabetic ulcers. Local PBM alongside usual care produced favourable changes in wound size; one of the tested dosing regimens had the best observed result. This concerns wound treatment, not nasal application or glucose reduction. [7]

The 2023 IWGDF guideline did not support routine use of physical therapies, including light, to heal diabetic ulcers because the evidence was uncertain and conflicting. Newer studies add knowledge; professional wound care, pressure offloading and management of infection or inadequate circulation remain essential. [10]

Neuropathic pain: a new controlled study

In a 2026 study, 64 participants were randomised to a local 640 + 405 nm laser or an inactive device. After three weeks, at least a 30% pain reduction was achieved by 72.7% versus 32.3% of participants. This is encouraging for short-term foot-pain relief. The study was manufacturer-funded, follow-up was short and some participants correctly guessed their allocation. It did not establish nerve regeneration or a cure for diabetes. [8]

Local PBM combined with wrist application

Another 2026 randomised pilot followed 26 participants. It compared local PBM, local PBM plus application over an artery at the wrist, and an inactive control. Some symptoms improved, but convincing superiority of one group was not established. The added value of vascular application therefore remains an open question. [9]

Microcirculation and blood vessels: what do we know about preventing complications?

Research explores vascular, metabolic and healing processes. However, these studies did not establish that laser irradiation reduces heart attacks, strokes or amputations. A short-term glucose change or smaller wound is not the same outcome as long-term vascular protection. [6][7]

Longer follow-up of complications is an important task for future research. The separate educational article Endothelium: the living lining of blood vessels explains the role of the vascular lining.

Frequently asked questions

Can laser light actually lower blood glucose?

Blood glucose fell in some human studies. Results depended on the application and protocol; this is not yet a guaranteed effect of every device. [1][3][4][6]

How might light affect mitochondria, ATP and glucose use?

Researchers are testing whether changes in cellular energy metabolism increase glucose use. A biological mechanism alone does not establish lasting clinical benefit. [4][5]

What does HbA1c show, and does lower glucose mean diabetes is cured?

HbA1c reflects average glucose over roughly three months. A one-off reduction does not establish remission or protection from complications. [13]

Is photobiomodulation an established diabetes treatment or still a research area?

For glucose control, it is an adjunctive approach under investigation. These studies do not justify replacing prescribed treatment with light. [3][4][6]

How do intravenous blood irradiation, skin application and nasal application differ?

ILIB delivers light into a vein. Transcutaneous and nasal applications pass through different tissues. A result from one route cannot automatically be attributed to another. [2][3]

Is red or blue laser light more effective in diabetes?

A small study of 24 patients found no significant difference between the tested blue and red light delivered intravenously. It does not identify the best colour for home use. [2]

Are home devices available, and what should I check?

Home light devices exist. Intended purpose, instructions, parameters and research on the particular application matter. A foot-pain result is not evidence of glucose control. [8]

How much does a procedure or home device cost?

There is no universal price. Compare a specific model or the complete course of procedures, including examination, applicators, servicing and follow-up.

Is laser therapy safe for people with diabetes, and when is caution needed?

Safety depends on the device and health condition. Reduced sensation may hide heat injury; a small study also reported temporary burning and redness. [6][12]

Could hypoglycaemia occur alongside insulin or medication?

The exact risk with photobiomodulation is unknown. Insulin and some diabetes medicines can cause hypoglycaemia, so monitoring and any medication changes should be agreed with a diabetes clinician. [4][11]

Does photobiomodulation help diabetic foot wounds and neuropathy?

Some local protocols have produced favourable wound-size or pain findings. These are different goals; the results do not establish a diabetes cure or effectiveness of nasal application. [7][8][9]

Does laser treatment improve microcirculation and prevent vascular complications?

Vascular and metabolic mechanisms are being investigated. These studies did not demonstrate fewer heart attacks, strokes or amputations. [6][7]

Sources and scientific references

References checked on 9 November 2026. For each study, we distinguish the participants, application method and measured outcome.

  1. Kazemi Khoo N et al. (2013). A metabolomic study on the effect of intravascular laser blood irradiation on type 2 diabetic patients. Lasers in Medical Science. DOI: 10.1007/s10103-012-1247-4.
    Original study: 9 patients; metabolites and glucose before and after intravenous application.
  2. KazemiKhoo N, Ansari F. (2015; online 2014). Blue or red: which intravascular laser light has more effects in diabetic patients? DOI: 10.1007/s10103-014-1672-7.
    Original comparative study: 24 patients; blue and red light during ILIB.
  3. Serry ZMH et al. (2021). Response of glycaemic control to extravascular low level laser therapy in type 2 diabetic patients: a randomized clinical trial. Physiotherapy Quarterly 29(4):42–48. DOI: 10.5114/pq.2021.105752.
    Randomised study: 60 patients; medication plus transcutaneous application versus medication alone; full-text PDF.
  4. Scontri CMCB et al. (2023). Dose and time-response effect of photobiomodulation therapy on glycemic control… Randomised crossover trial. DOI: 10.1002/jbio.202300083.
    Original study: 10 patients; LEDs over muscle areas and a control without active light.
  5. Powner MB, Jeffery G. (2024). Light stimulation of mitochondria reduces blood glucose levels. Journal of Biophotonics. DOI: 10.1002/jbio.202300521.
    Original study: 30 healthy participants; 670 nm light and a glucose tolerance test.
  6. Almeida LA et al. (2026). Effects of Vascular Photobiomodulation on Glycemic Control in Patients With Type II Diabetes Mellitus: A Prospective Single-Arm Clinical Study. DOI: 10.1002/lsm.70192.
    Original study: 15 patients; 660 nm through the skin over the radial artery for six weeks.
  7. Cardoso VS et al. (2024). Dose-response and efficacy of 904 nm photobiomodulation on diabetic foot ulcers healing: a randomized controlled trial. DOI: 10.1007/s10103-024-04090-3.
    Randomised study: 80 participants with non-infected diabetic ulcers; local treatment.
  8. Franco S et al. (2026). Dual-Wavelength Laser Therapy for Painful Diabetic Peripheral Neuropathy: A Randomized, Double-Blind, and Sham-Controlled Trial. DOI: 10.1155/prm/8710857.
    Randomised study: 64 participants; local 640 + 405 nm laser for foot pain; manufacturer-funded.
  9. Photobiomodulation with or without ILIB in diabetic peripheral neuropathy: a randomized pilot trial (2026). PMID: 42430054.
    Randomised pilot: 26 participants; ILIB in this paper means application through the skin over an artery, not a fibre inserted into a vein.
  10. International Working Group on the Diabetic Foot (IWGDF). Guidelines 2023 – Wound Healing Guideline, recommendation 15.
    Clinical guideline on diabetic ulcer healing and the role of physical therapies.
  11. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Low Blood Glucose (Hypoglycemia).
    Official information on low glucose, medicines associated with risk and management of hypoglycaemia.
  12. NIDDK. Diabetes & Foot Problems.
    Official information on sensation, circulation, wounds and protecting diabetic feet from heat.
  13. NIDDK. The A1C Test & Diabetes.
    Explanation of HbA1c and its difference from a single glucose measurement.
Ing. František Kokoš
Author: Ing. František Kokoš
Ing. František Kokoš – Author of KINGRAY Academy and Advice Corner
Technician, nutrition adviser (graduate of the 150-hour Welko retraining programme, 2025) and creator of the KINGRAY nutraceuticals concept. Years of developing the BIOquant medical device and working with blood rheology and tissue oxygenation led him to realise that bodily health requires the full picture – linking microcirculation, cellular energy and proper nutrition. In his articles, he looks for the balance where the body understands and cooperates with us.
He is the author of the book Liečba svetlom (Light Therapy, ISBN 978-80-970512-0-4), co-author of the publication BIOquant – polovodičová laserová terapia (BIOquant – Semiconductor Laser Therapy, ISBN 978-80-970512-2-8), and originator of patents in light technologies (US9731145B2, SK5457Y1).
%s ...
%s
%image %title %code %s
%s